Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 11, 2014, Pages 6879-6885

  Dolton, Michael J ^a,b   Brüggemann, Roger J M ^c   Burger, David M ^c   McLachlan, Andrew J ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Department of Geriatric Medicine   (Australia)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FOSAMPRENAVIR; METOCLOPRAMIDE; PHENYTOIN; POSACONAZOLE; PROTON PUMP INHIBITOR; RANITIDINE; RIFAMPICIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTICONVULSIVE AGENT; ANTIEMETIC AGENT; ANTIFUNGAL AGENT; CARBAMIC ACID DERIVATIVE; NUCLEIC ACID SYNTHESIS INHIBITOR; ORGANOPHOSPHATE; SULFONAMIDE; TRIAZOLE DERIVATIVE;

ADULT; ARTICLE; CONTROLLED STUDY; DIARRHEA; DIET SUPPLEMENTATION; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXPOSURE; DRUG INHIBITION; DRUG MONITORING; DRUG POTENTIATION; FEMALE; FOOD; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MYCOSIS; PHARMACOKINETICS; SENSITIVITY ANALYSIS; STEADY STATE; VOLUME OF DISTRIBUTION; ADVERSE EFFECTS; BIOAVAILABILITY; COMBINATION DRUG THERAPY; DRUG INTERACTION; NORMAL HUMAN;

ADULT; ANTI-HIV AGENTS; ANTICONVULSANTS; ANTIEMETICS; ANTIFUNGAL AGENTS; BIOLOGICAL AVAILABILITY; CARBAMATES; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HEALTHY VOLUNTEERS; HUMANS; METOCLOPRAMIDE; NUCLEIC ACID SYNTHESIS INHIBITORS; ORGANOPHOSPHATES; PHENYTOIN; PROTON PUMP INHIBITORS; RIFAMPIN; SULFONAMIDES; TRIAZOLES;

EID: 84908299224     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03777-14     Document Type: Article

References (44)

1. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh Y-T, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D. 2007. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 356:348-359. http://dx.doi.org/10.1056/NEJMoa061094.
2. Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R, Greene RE, Hachem R, Hadley S, Herbrecht R, Langston A, Louie A, Ribaud P, Segal BH, Stevens DA, van Burik J-AH, White CS, Corcoran G, Gogate J, Krishna G, Pedicone L, Hardalo C, Perfect JR. 2007. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin. Infect. Dis. 44:2-12. http://dx.doi.org/10.1086/508774.
3. Ezzet F, Wexler D, Courtney R, Krishna G, Lim J, Laughlin M. 2005. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin. Pharmacokinet. 44:211-220. http://dx.doi.org/10.2165/00003088-200544020-00006.
4. Krishna G, Moton A, Ma L, Medlock MM, McLeod J. 2009. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob. Agents Chemother. 53:958-966. http://dx.doi.org/10.1128/AAC.01034-08.
5. Walravens J, Brouwers J, Spriet I, Tack J, Annaert P, Augustijns P. 2011. Effect of pH and comedication on gastrointestinal absorption of posaconazole. Clin. Pharmacokinet. 50:725-734. http://dx.doi.org/10.2165/11592630-000000000-00000.
6. Dolton MJ, Ray JE, Chen SCA, Ng K, Pont L, McLachlan AJ. 2012. Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration. Antimicrob. Agents Chemother. 56:5503-5510. http://dx.doi.org/10.1128/AAC.00802-12.
7. Ray J, Campbell L, Rudham S, Nguyen Q, Marriott D. 2011. Posaconazole plasma concentrations in critically ill patients. Ther. Drug Monit. 33:387-392. http://dx.doi.org/10.1097/FTD.0b013e31821fb197.
8. Brüggemann RJM, Alffenaar J-WC, Blijlevens NMA, Billaud EM, Kosterink JGW, Verweij PE, Burger DM, Saravolatz LD. 2009. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin. Infect. Dis. 48:1441-1458. http://dx.doi.org/10.1086/598327.
9. Dolton MJ, Ray JE, Marriott D, Mclachlan AJ. 2012. Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring. Antimicrob. Agents Chemother. 56:2806-2813. http://dx.doi.org/10.1128/AAC.05900-11.
10. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, Greinix H, Morais de Azevedo W, Reddy V, Boparai N, Pedicone L, Patino H, Durrant S. 2007. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med. 356:335-347. http://dx.doi.org/10.1056/NEJMoa061098.
11. Jang SH, Colangelo PM, Gobburu JVS. 2010. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin. Pharmacol. Ther. 88:115-119. http://dx.doi.org/10.1038/clpt.2010.64.
12. Cornely OA, Ullmann AJ. 2011. Lack of evidence for exposure-response relationship in the use of posaconazole as prophylaxis against invasive fungal infections. Clin. Pharmacol. Ther. 89:351-352. http://dx.doi.org/10.1038/clpt.2010.261.
13. Seyedmousavi S, Mouton JW, Verweij PE, Brüggemann RJ. 2013. Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis. Expert Rev. Anti Infect. Ther. 11:931-941. http://dx.doi.org/10.1586/14787210.2013.826989.
14. Crombag M-RBS, Huisman C, Kemper EM, Brüggemann RJM, Bijleveld YA. 2012. Posaconazole treatment in hematology patients: a pilot study of therapeutic drug monitoring. Ther. Drug Monit. 34:320-325. http://dx.doi.org/10.1097/FTD.0b013e31824d135c.
15. Mavridou E, Bruggemann RJM, Melchers WJG, Mouton JW, Verweij PE. 2010. Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. Antimicrob. Agents Chemother. 54:860-865. http://dx.doi.org/10.1128/AAC.00931-09.
16. Eiden C, Meniane JC, Peyrière H, Eymard-Duvernay S, Le Falher G, Ceballos P, Fegueux N, Cociglio M, Reynes J, Hillaire-Buys D. 2011. Therapeutic drug monitoring of posaconazole in hematology adults under posaconazole prophylaxis: influence of food intake. Eur. J. Clin. Microbiol. Infect. Dis. 31:161-167. http://dx.doi.org/10.1007/s10096-011-1288-9.
17. Hoenigl M, Raggam RB, Salzer HJF, Valentin T, Valentin A, Zollner-Schwetz I, Strohmeier AT, Seeber K, Wölfler A, Sill H, Krause R. 2012. Posaconazole plasma concentrations and invasive mould infections in patients with haematological malignancies. Int. J. Antimicrob. Agents 39:510-513. http://dx.doi.org/10.1016/j.ijantimicag.2012.02.002.
18. Thompson GR, Rinaldi MG, Pennick G, Dorsey SA, Patterson TF, Lewis JS. 2009. Posaconazole therapeutic drug monitoring: a reference laboratory experience. Antimicrob. Agents Chemother. 53:2223-2224. http://dx.doi.org/10.1128/AAC.00240-09.
19. Bryant AM, Slain D, Cumpston A, Craig M. 2011. A post-marketing evaluation of posaconazole plasma concentrations in neutropenic patients with haematological malignancy receiving posaconazole prophylaxis. Int. J. Antimicrob. Agents 37:266-269. http://dx.doi.org/10.1016/j.ijantimicag.2010.11.021.
20. Merck Inc. 2014. Noxafil prescribing information, revised 11/2013. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/205053s000lbl.pdf. Accessed 3 March 2014.
21. Brüggemann RJM, Van Luin M, Colbers EPH, van den Dungen MW, Pharo C, Schouwenberg BJJW, Burger DM. 2010. Effect of posaconazole on the pharmacokinetics of fosamprenavir and vice versa in healthy volunteers. J. Antimicrob. Chemother. 65:2188-2194. http://dx.doi.org/10.1093/jac/dkq280.
22. Shen J, Boeckmann A, Vick A. 2012. Implementation of dose superimposition to introduce multiple doses for a mathematical absorption model (transit compartment model). J. Pharmacokinet. Pharmacodyn. 39:251-262. http://dx.doi.org/10.1007/s10928-012-9247-3.
23. Bergstrand M, Hooker A, Wallin J, Karlsson M. 2011. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models.AAPS J. 13:143-151. http://dx.doi.org/10.1208/s12248-011-9255-z.
24. AbuTarif MA, Krishna G, Statkevich P. 2010. Population pharmacokinetics of posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Curr. Med. Res. Opin. 26:397-405. http://dx.doi.org/10.1185/03007990903485056.
25. Kohl V, Müller C, Cornely OA, Abduljalil K, Fuhr U, Vehreschild JJ, Scheid C, Hallek M, Rüping MJGT. 2010. Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. Antimicrob. Agents Chemother. 54:207-212. http://dx.doi.org/10.1128/AAC.01027-09.
26. Vehreschild JJ, Müller C, Farowski F, Vehreschild MJ, Cornely OA, Fuhr U, Kreuzer KA, Hallek M, Kohl V. 2012. Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome. Eur. J. Clin. Pharmacol. 68:987-995. http://dx.doi.org/10.1007/s00228-012-1212-y.
27. European Medicines Agency. 2005. Noxafil: EPAR - scientific discussion. European Medicines Agency, London, United Kingdom. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Scientific-Discussion/human/000610/WC500037781.pdf. Accessed 1 November 2013.
28. Krishna G, Ma L, Vickery D, Yu X, Wu I, Power E, Beresford E, Komjathy S. 2009. Effect of varying amounts of a liquid nutritional supplement on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob. Agents Chemother. 53:4749-4752. http://dx.doi.org/10.1128/AAC.00889-09.
29. Krishna G, AbuTarif M, Xuan F, Martinho M, Angulo D, Cornely OA. 2008. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Pharmacotherapy 28:1223-1232. http://dx.doi.org/10.1592/phco.28.10.1223.
30. Krishna G, Martinho M, Chandrasekar P, Ullmann AJ, Patino H. 2007. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy 27:1627-1636. http://dx.doi.org/10.1592/phco.27.12.1627.
31. Cornely OA, Helfgott D, Langston A, Heinz W, Vehreschild JJ, Vehreschild MJGT, Krishna G, Ma L, Huyck S, McCarthy MC. 2012. Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection. Antimicrob. Agents Chemother. 56:2652-2658. http://dx.doi.org/10.1128/AAC.05937-11.
32. Lebeaux D, Lanternier F, Elie C, Suarez F, Buzyn A, Viard J-P, Bougnoux M-E, Lecuit M, Jullien V, Lortholary O. 2009. Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults. Antimicrob. Agents Chemother. 53:5224-5229. http://dx.doi.org/10.1128/AAC.00939-09.
33. Krishna G, Sansone-Parsons A, Kantesaria B. 2007. Drug interaction assessment following concomitant administration of posaconazole and phenytoin in healthy men. Curr. Med. Res. Opin. 23:1415-1422. http://dx.doi.org/10.1185/030079907X187937.
34. Krishna G, Parsons A, Kantesaria B, Mant T. 2007. Evaluation of the pharmacokinetics of posaconazole and rifabutin following coadministration to healthy men. Curr. Med. Res. Opin. 23:545-552. http://dx.doi.org/10.1185/030079906X167507.
35. Hohmann C, Kang EM, Jancel T. 2010. Rifampin and posaconazole coadministration leads to decreased serum posaconazole concentrations. Clin. Infect. Dis. 50:939-940. http://dx.doi.org/10.1086/650740.
36. Lipp H-P. 2010. Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: an overview. Br. J. Clin. Pharmacol. 70:471-480. http://dx.doi.org/10.1111/j.1365-2125.2010.03680.x.
37. Ghosal A, Hapangama N, Yuan Y, Achanfuo-Yeboah J, Iannucci R, Chowdhury S, Alton K, Patrick JE, Zbaida S. 2004. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil). Drug Metab. Dispos. 32:267-271. http://dx.doi.org/10.1124/dmd.32.2.267.
38. Anderson GD. 2004. Pharmacogenetics and enzyme induction/inhibition properties of antiepileptic drugs. Neurology 63(10 Suppl 4):S3-S8. http://dx.doi.org/10.1212/WNL.63.10-suppl-4.S3.
39. Oesch F, Arand M, Benedetti MS, Castelli MG, Dostert P. 1996. Inducing properties of rifampicin and rifabutin for selected enzyme activities of the cytochrome P-450 and UDP-glucuronosyltransferase superfamilies in female rat liver. J. Antimicrob. Chemother. 37:1111-1119. http://dx.doi.org/10.1093/jac/37.6.1111.
40. Dodds Ashley ES, Varkey JB, Krishna G, Vickery D, Ma L, Yu X, Malavade D, Goodwin M, Perfect JR, Power E. 2009. Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers. Antimicrob. Agents Chemother. 53:2960-2964. http://dx.doi.org/10.1128/AAC.01178-08.
41. Störzinger D, Borghorst S, Hofer S, Busch CJ, Lichtenstern C, Hempel G, Weigand MA, Hoppe-Tichy T. 2012. Plasma concentrations of posaconazole administered via nasogastric tube in patients of a surgical intensive care unit. Antimicrob. Agents Chemother. 56:4468-4470. http://dx.doi.org/10.1128/AAC.06167-11.
42. Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R, Hope WW. 2014. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J. Antimicrob. Chemother. 69:1162-1176. http://dx.doi.org/10.1093/jac/dkt508.
43. Dolton MJ, Mikus G, Weiss J, Ray JE, McLachlan AJ. 2014. Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing. J. Antimicrob. Chemother. 69:1633-1641. http://dx.doi.org/10.1093/jac/dku031.
44. Ullmann AJ, Cornely OA, Burchardt A, Hachem R, Kontoyiannis DP, Töpelt K, Courtney R, Wexler D, Krishna G, Martinho M, Corcoran G, Raad I. 2006. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob. Agents Chemother. 50:658-666. http://dx.doi.org/10.1128/AAC.50.2.658-666.2006.